Physician profile
James J Bazzi
NPI 1700265014
$367,958.38
in general payments reported to CMS, 2019-2025
23 companies · $304K in 2025
The $304K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $384 · 2021: $1,337 · 2022: $1,185 · 2023: $1,529 · 2024: $59K · 2025: $304K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $323K · Travel and Lodging: $29K · Food and Beverage: $12K · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $323,150.00 |
| Travel and Lodging | $29,203.20 |
| Food and Beverage | $12,021.86 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363,676.52 | 2021-2025 | Botox |
| Glaxosmithkline, LLC. | $1,349.09 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Allergan, INC. | $671.05 | 2021-2022 | |
| Novo Nordisk INC | $356.07 | 2019-2022 | |
| Galderma Laboratories, L.P. | $230.75 | 2022-2024 | |
| Pfizer INC. | $201.05 | 2019-2021 | |
| Amgen INC. | $196.43 | 2019-2021 | |
| Revance Therapeutics, INC. | $188.56 | 2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.56 | 2019-2022 | |
| Lilly USA, LLC | $150.70 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $139.12 | 2019-2020 | |
| Daiichi Sankyo INC. | $124.55 | 2023 | Injectafer |
| Pharmacosmos Therapeutics INC. | $124.23 | 2021 | |
| Janssen Pharmaceuticals, INC | $98.33 | 2019-2022 | |
| Astellas Pharma US INC | $59.44 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $47.84 | 2019-2020 | |
| Merz North America, INC. | $33.57 | 2024 | |
| Merck Sharp & Dohme LLC | $24.16 | 2019-2020 | |
| Sanofi Pasteur INC. | $14.80 | 2019 | |
| Boston Scientific Corporation | $13.51 | 2019 | |
| Smith+Nephew, INC. | $12.60 | 2019 | |
| Gilead Sciences, INC. | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bazzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.